← All trials
NCT01119014
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2010
- Primary completion
- Feb 1, 2015
- Completion date
- Jul 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of CopenhagenLead sponsor
- Aarhus UniversityOverall official - principal investigator
- University of CopenhagenCollaborator
- Sct. Hans Hospital, DenmarkOverall official - principal investigator
- University of Southern DenmarkOverall official - principal investigator
- University of CopenhagenOverall official - principal investigator
- University of CopenhagenSponsor investigator
- The Research Council for Health and Disease, DenmarkCollaborator
- Allocated inheritance from Elizabeth Stevn and Niels Rindom, DenmarkCollaborator
- AP Moeller FoundationCollaborator
- Government of DenmarkCollaborator
- Yeshiva UniversityCollaborator
- Sct. Hans Hospital, DenmarkCollaborator
- TRYG FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.